Browse Pugatch Consilium's full catalogue of reports, publications, and data resources. Open-access items are available to all visitors. Premium and members-only content requires a subscription.
Explore the 14th edition data through interactive charts and maps. Includes global rankings, country profiles, category breakdowns, and head-to-head comparisons across all 55 economies.
The complete 14th edition of the International IP Index, providing in-depth analysis of IP frameworks, enforcement, and innovation outcomes across 55 global economies.
The executive summary of the 13th edition of the International IP Index, benchmarking intellectual property environments across 55 economies worldwide.
The latest BCI Report assessing the competitiveness of biopharmaceutical R&D investment environments, covering policy frameworks, market conditions, and innovation indicators across key economies.
The second edition of the Congressional Innovation Scorecard, evaluating U.S. legislators' voting records and policy positions on intellectual property and innovation.
The sixth edition covers 44 countries, examining pro-innovation policy frameworks and their correlation with biotechnology outputs across 28 indicators.
Examining national biotech policy frameworks across 33 countries, with analysis of how regulatory and IP environments drive biotechnology investment.
Quantifying the impact of policy on biotechnology innovation across leading markets. Includes full statistical annex.
Assessing the global race for biopharmaceutical innovation leadership and the policy frameworks driving competitive advantage.
Measuring the biomedical pulse of leading economies with a comprehensive set of indicators spanning policy inputs and biotechnology outputs.
The inaugural edition examining national biotechnology industry development strategies, policies, and best practices across major economies.
Benchmarking the national IP environment across 50 countries. The index demonstrates the strong relationship between IP strength and innovation outcomes.
Fifth annual benchmark assessing IP environments and their relationship with long- and short-term business and investment decisions across 45 economies.
The inaugural edition of the International IP Index, establishing the foundational methodology for benchmarking national IP environments globally.
A comprehensive analysis of global clinical trial activity, identifying the policy and regulatory factors that shape where clinical research is conducted.
Analysis of the European Medicines Agency regulatory environment and its implications for pharmaceutical innovation and market access in Europe.
Assessment of generic drug appraisal and approval processes in the US market, examining regulatory efficiency and its impact on market competition.
Examining the policy and regulatory levers that determine access to medicines across healthcare systems, with a focus on IP, pricing, and market structure.
Analysis of patient-centred market access frameworks, examining how health systems can better align access policies with patient outcomes and needs.
An in-depth examination of the unintended consequences of market access and pricing policies in biopharmaceutical markets across key economies.
A comprehensive assessment of AI adoption readiness across pharmaceutical sectors, covering regulatory frameworks, data infrastructure, and strategic positioning.
Exploring the innovation landscape and the strategic choices facing firms and policymakers in knowledge-intensive sectors over the coming decade.
Identifying the next frontier of innovation policy challenges and opportunities across life sciences, IP, and emerging technology sectors.
An analysis of how countries can build robust pharmacovigilance systems to improve medicine safety monitoring and reporting across health systems.
Foundational study on medicine safety frameworks, examining how regulatory systems can be strengthened to protect patients while supporting innovation.
A Pugatch Consilium membership unlocks premium reports, country presentations, members-only publications, and future interactive tools.